Navigation Links
Stem Cells Might Beat Drugs in Delivering Relief Faster, More Effectively to Rheumatoid Arthritis Sufferers
Date:4/16/2013

Durham, NC (PRWEB) April 16, 2013

Can stem cell therapy outperform a drug commonly considered the gold standard for treating rheumatoid arthritis? A new study in rodents published in the current issue of STEM CELLS Translational Medicine indicates perhaps so.

The findings could lead to a faster, safer, more effective way to bring relief to the up to 70 million people estimated to suffer from this disease worldwide.

Rheumatoid arthritis (RA) is a chronic condition that causes pain, stiffness, swelling and limited motion and function of many joints. While it can affect any joint, RA tends to settle mainly in a patient’s hands and feet. The results can be debilitating.

People who have RA overproduce a protein called tumor necrosis factor (TNF), which causes the inflammation and damage to the bones, cartilage and tissue. Anti-TNF drugs can block the action of the protein and reduce inflammation. Etanercept® (marketed under the trade name Enbrel) is a type of anti-TNF drug called a biologic that for years has been prescribed to treat RA. However, it can’t be targeted specifically to the site of the arthritis and, thus, requires higher doses that can cause serious side effects including fatal infections, multiple sclerosis, seizures, heart failure, cancer and more.

“Moreover, biologics in general require intense development and manufacturing processes that are challenging for reproducibility, even within the same company. So we wanted to see how delivering treatment through a very targeted system such as that which can be done using stem cells compared to a biologic drug such as Etanercept®,” said Joseph Mosca, Ph.D. He led the team of researchers from Osiris Therapeutics, Inc. Baltimore, Md., and the Novartis Research, Basel, Switzerland, in conducting the study.

The researchers began by genetically altering human mesenchymal stem cells (MSCs) in the lab to become vehicles for the cell-based anti-TNF delivery. They then injected the cells into mice that had been induced with RA and monitored them over a seven-day period, then compared the results to a group of animals treated with Etanercept®. The results showed that the anti-TNF therapy delivered by stem cells reversed or attenuated the arthritis inflammation on par with the Etanercept® — except that it did it faster.

“If this translates into fewer side-effects and/or lower compliance remains to be seen,” Dr. Mosca said. “In either case, these results illustrate the ability of stem cells to deliver proteins of therapeutic value and demonstrate their potential clinical utility in rheumatoid/osteoarthritis and other TNF-related diseases where anti-TNF biologic drugs have already shown promise.”

“The authors have shown the feasibility of a targeted approach to treatment using cells that are known to ‘home’ to damaged tissue,” said Anthony Atala, M.D., Editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “The manuscript supports and demonstrates the potential of mesenchymal stem cells as a vehicle for cell-based gene delivery.”

###
The full article, “Comparison of Drug and Cell-Based Delivery—Engineered Adult Mesenchymal Stem Cells Expressing Soluble Tumor Necrosis Factor Receptor-II Prevent Arthritis in Mouse and Rat Animal Models,” can be accessed at http://www.stemcellstm.com.

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), in its 31st year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10635431.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Preliminary Research, Led By Dr. Vincent Giampapa, Finds Aged Adult Stem Cells Can Be Functionally Reprogrammed To Act Like Younger Cells
2. New Method for Mass-Producing RPE Cells Paves Way to Treating Age-Related Blindness
3. Sigma Life Science and the Culture Collections of Public Health England Collaborate to Distribute Cells and Cellular Extracts
4. New Way to Mass-produce Natural Cancer-killing Cells Offers Hope for Patients
5. Tenfold boost in ability to pinpoint proteins in cancer cells
6. Stem cells produce compact, regenerated bone in mandible transplants
7. Transplanted brain cells in monkeys light up personalized therapy
8. U of T engineering breakthrough promises significantly more efficient solar cells
9. Dr. Carlos Szajnert, Announced today his Commitment to Further Educate his Patients on the Benefits of Cord Blood Stem Cells
10. UCLA researchers further refine NanoVelcro device to grab single cancer cells from blood
11. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently ... have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. ... for gene editing across all applications. , Under the terms of the agreement, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
Breaking Biology News(10 mins):